Novartis Reports Six-Year Kisqali NATALEE Analysis in Early Breast Cancer
Novartis says a six-year analysis of Kisqali in HR+/HER2- early breast cancer deepens understanding of the disease.
Novartis says a six-year analysis of Kisqali in HR+/HER2- early breast cancer deepens understanding of the disease.